Niresh Hariparsad

Head, DMPK Boston, Oncology R&D AstraZeneca

Niresh is an experienced scientist with a demonstrated body of work at large pharmaceutical and biotechnology companies supporting projects including, but not limited to, oncologic, renal, infectious and CNS disorders. He has expertise in the management of drug progression, as the DMPK and Clinical Pharmacology lead, from discovery to NDA across global regions with extensive knowledge in the preparation and review of documents including INDs, BLAs, and IBs for regulatory submission. Niresh was the DMPK lead involved in the discovery and early clinical development of Inaxaplin (renal disease) and Camizestrant (breast cancer). He is involved in the support of projects spanning various modalities including ADCs, radio-immunoconjugates, immune engagers, PROTACS, and small molecules.

Seminars

Tuesday 24th February 2026
Evaluating Novel ADC Payload Preclinical Characterisation to Set Up In-Human Translation for Success
2:00 pm
  • Laying out the hurdles for novel payload PK/PD characterisation without substantial historical data
  • Breaking down novel payload ADME and PK/PD considerations for translation
  • Understanding ideal attributes to observe to best set up next-generation payload translation for success
Niresh Hariparsad Speaker Photo - 16th World ADC London Summit